Yellow fever

World Health Organization. Yellow fever: fact sheet. May 2023 [internet publication].Full text

Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Full text  Abstract

Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Full text

1. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Full text  Abstract

2. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Abstract

3. World Health Organization. Yellow fever: fact sheet. May 2023 [internet publication].Full text

4. World Health Organization. Disease outbreak news. Yellow fever - Mali. December 2019 [internet publication].Full text

5. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2017 [internet publication].Full text

6. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2019 [internet publication].Full text

7. World Health Organization. Winning the war against yellow fever. November 2016 [internet publication].Full text

8. World Health Organization. Weekly epidemiological record. Yellow fever in Africa and the Americas, 2017. August 2018 [internet publication].Full text

9. Wilder-Smith A, Monath TP. Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017;17:248-250.Full text  Abstract

10. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-related infectious diseases - yellow fever. May 2023 [internet publication].Full text

11. World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370-6. Abstract

12. World Health Organization: Global Response and Alert (GAR). Yellow fever: a current threat. 2017 [internet publication].

13. Vasconcelos PF, Costa ZG, Travassos da Rosa ES, et al. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. J Med Virol. 2001;65:598-604. Abstract

14. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. Abstract

15. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Full text  Abstract

16. Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization - recommendations of the ACIP. MMWR Recomm Rep. 2011;60:1-64.Full text  Abstract

17. Centers of Disease Control and Prevention. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:324-325.Full text  Abstract

18. Cornet JP, Huard M, Camicas JL, et al. Experimental transmission of the yellow fever virus by the tick Amblyomma variegatum (F.). Bull Soc Pathol Exot Filiales. 1982;75:136-140. Abstract

19. Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Full text  Abstract

20. World Health Organization. Yellow fever-Brazil. April 2019 [internet publication].Full text

21. Pan American Health Organization, World Health Organization. Epidemiological update: yellow fever. Dec 2018 [internet publication].Full text

22. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. Abstract

23. Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change - a decision too feverish? Clin Microbiol Infect. 2013;19:885-886. Abstract

24. World Health Organization Department of Immunization, Vaccines and Biologicals. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. July 2016 [internet publication].Full text

25. Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N Engl J Med. 2019 Aug 1;381(5):444-454.Full text  Abstract

26. Roukens AHE, van Halem K, de Visser AW, et al. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018 Dec 4;169(11):761-5. Abstract

27. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29:4544-4555. Abstract

28. Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267-1271. Abstract

29. Traiber C, Coelho-Amaral P, Ritter VR, et al. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J). 2011;87:269-272. Abstract

30. Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;(1):CD010929.Full text  Abstract

31. Nascimento Silva JR, Camacho LA, Siqueira MM, et al; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327-6334. Abstract

32. Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. April 2019 [internet publication].Full text

33. Mirzaian E, Durham MJ, Hess K, et al. Mosquito-borne illnesses in travelers: a review of risk and prevention. Pharmacotherapy. 2010;30:1031-1043. Abstract

34. Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Full text

35. Drosten C, Göttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-2330.Full text  Abstract

36. Domingo C, Patel P, Yillah J, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-4060. Abstract

37. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Full text  Abstract

38. Centers for Disease Control and Prevention. National Notifiable Disease Surveillance System (NNDSS): yellow fever, 2019 case definition. Apr 2021 [internet publication].Full text

39. World Health Organization. CDC and WHO launch trial version of a new ELISA: a kit, simpler and faster to perform. July 2018 [internet publication].

40. World Health Organization.Yellow fever: case definitions for public health surveillance. May 2015 [internet publication].Full text

41. Centers for Disease Control and Prevention. Yellow fever: diagnostic testing. August 2015 [internet publication].Full text

42. Monath TP. Treatment of yellow fever. Antiviral Res. 2008;78:116-124. Abstract

43. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(suppl 4):S750-S761. Abstract

44. Arroyo JI, Apperson SA, Cropp CB, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988;38:647-650. Abstract

45. Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013;97:169-179. Abstract

46. Centers for Disease Control and Prevention. Testing of selected patients with serious adverse events potentially related to yellow fever vaccination. August 2015 [internet publication].Full text

47. Borio L, Inglesby T, Peters CJ, et al; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405. Abstract

48. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51:989-993.Full text  Abstract

49. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-666. Abstract

50. ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190:1821-1827.Full text  Abstract

51. Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358:84-85. Abstract

52. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. Abstract

53. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill. 2004;9:E11-E12.Full text  Abstract